Comparative Pharmacology
Head-to-head clinical analysis: DILOR 400 versus FORADIL CERTIHALER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILOR 400 versus FORADIL CERTIHALER.
DILOR-400 vs FORADIL CERTIHALER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phosphodiesterase inhibitor; inhibits PDE4 and PDE5, leading to increased intracellular cAMP and cGMP, resulting in bronchodilation and vasodilation.
Formoterol is a long-acting beta2-adrenergic receptor agonist that stimulates intracellular adenyl cyclase, increasing cyclic AMP production and causing bronchodilation.
400 mg orally every 6 to 8 hours; maximum daily dose 2400 mg.
One inhalation (12 mcg) twice daily via oral inhalation.
None Documented
None Documented
3.1 hours (terminal elimination half-life; may increase in hepatic impairment or congestive heart failure)
The terminal elimination half-life of formoterol (active component) ranges from 5 to 10 hours following inhalation. This supports twice-daily dosing, though clinical effect may persist longer due to prolonged receptor binding.
Renal (70% unchanged), hepatic metabolism (30%)
After oral inhalation, the majority of a dose is excreted in feces (up to 70%) as unchanged drug and metabolites via biliary elimination. Renal excretion accounts for approximately 13-25% of the dose, primarily as metabolites. Unabsorbed drug accounts for the remainder.
Category C
Category C
Bronchodilator
Bronchodilator